Crossmark

Comparative pharmacokinetics for bioequivalence of pramipexole dihydrochloride extended-release tablets in fasting and fed Chinese healthy volunteers: a randomized, open-label, single-dose, crossover study

Crossref DOI link: https://doi.org/10.1186/s40360-026-01144-w

Published Online: 2026-05-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Qian

Shi, Hui-qing

Chen, Yi-fang

Zhang, Wei

Ye, Lan

Li, Ya-ming

Hu, Ting-ting
Funding

Funding for this research was provided by:

Haisco Pharmaceutical Group Co., Ltd
License Information

Text and Data Mining valid from 2026-05-11

Accepted Manuscript valid from 2026-05-11
More Information

Article History

Received: 27 October 2025

Accepted: 23 April 2026

First Online: 11 May 2026

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and its amendments, the International Council for Harmonization Good Clinical Practice (GCP) guidelines, and local laws and regulations. The Ethics Committee (The General Hospital of Western Theater Command PLA Ethics Committee) approved the study prior to enrollment (approval number: 2017 EC-Drug 01). The participants provided informed consent prior to their screening procedures.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below